JPRN-jRCT2080222622未知1 期
An open-label, non-randomized, single-sequence study to evaluate the effects of DS-8500a on the pharmacokinetics of midazolam in Japanese healthy subjects
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 28 人开始时间: 2014年10月7日最近更新:
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- All
入选标准
- •1) Japanese
- •2) Between the age of 20 and 45
- •3) Between the BMI of 18.5 and 25.0
- •4) HbA1c < 6.5%
- •5) Between the fasting blood glucose level of 70 mg/dL and 109 mg/d
排除标准
- •1) Presence or history of severe adverse reaction to any drug including midazolam or sensitivity.
- •2) Presence or history of drug or alcohol abuse. etc.
研究者
相似试验
已完成
1 期
A study to investigate the effect of enzyme inhibition on the bodily processing of RO6953958 in healthy participantson-respiratory sleep disturbances in people with neurodevelopmental disorders (NDDs)Nervous System DiseasesISRCTN10164855Roche (Switzerland)16
已完成
不适用
An open-label, non-randomized, fixed-sequence crossover study to investigate the effects of the proton pump inhibitor esomeprazole on the pharmacokinetics of elinzanetant (BAY 3427080) as well as assessment of the absolute bioavailability of elinzanetant using a single intravenous microtracer dose of [13C5]BAY 3427080 in male and female healthy participants.NL-OMON50454Bayer AG14
已完成
3 期
Clinical trial on healthy subjects for general healthCTRI/2021/02/031064IndusViva HealthSciences Pvt Ltd40
尚未招募
3 期
This is a clinical study to evaluate efficacy, pharmacokinetic and safety of human with normal immunoglobulin for intravenous administration in patients with primary immunodeficiency diseases.CTRI/2022/12/048138Intas Pharmaceutical Ltd India
进行中（未招募）
不适用
Dose titration study to evaluate efficacy and safety of Botulinum toxin type A to treat spasticity in the leg and armEUCTR2010-020886-26-ESMerz Pharmaceuticals GmbH150